Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma
Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
This systematic review and meta-analysis evaluated first-line treatment for unresectable hepatocellular carcinoma in East Asian populations.…
A meta-analysis of East Asian patients with unresectable liver cancer found lenvatinib-based regimens improved survival compared to bevacizu…
Systematic review and meta-analysis compares subcutaneous versus intravenous PD-1/PD-L1 inhibitors for solid tumors.
Subcutaneous shots match intravenous drugs for cancer survival and response rates in solid tumors.
This systematic review and meta-analysis of 1243 patients with solid tumors found no significant difference in overall survival, progression…
A large review found that giving cancer drugs under the skin works just as well as the traditional vein injection for patients with solid tu…
Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 show improved risk discrimination for immune-toxicity-associated systemic injury.
New Tool Predicts Immune Drug Organ Damage
This translational multicohort study evaluated patients receiving immune checkpoint inhibitors in United States electronic health record dat…
A new system helps doctors predict which patients might suffer dangerous organ injury from powerful cancer drugs, giving them time to act so…
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…